Paliperidone, Serum or Plasma
2007949
Ordering Recommendation
Therapeutic monitoring of paliperidone (eg, Invega).
Mnemonic
PALIPERID
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun, Wed
Reported
1-5 days
N/A
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Pre-dose (trough) draw - At steady state concentration.  
Collect
Lavender (EDTA), pink (K2EDTA) or plain red.  
Specimen Preparation
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).  
Remarks
N/A  
Stability
Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 months  
Reference Interval
 
 
Therapeutic range: Not well established
Proposed Dose-​Related Range: Paliperidone (9-​hydroxyrisperidone): 20 -​ 60 ng/mL
Toxic range: Not well established
Interpretive Data
Adverse effects to paliperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension and dyskinesia.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
80299
Components
Component Test Code*Component Chart Name
2007950Paliperidone, Serum/Plasma
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • 9-hydroxyrisperidone
  • Invega
  • invega blood level